NLSP - NLS Pharmaceutics AG

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
-15,984
-16,496
-11,946
-2,861
-5,447
Depreciation & amortisation
10.732
11.408
10.05
-
-
Stock-based compensation
22.73
22.73
-
-
-
Change in working capital
3,082
1,627
-3,167
2,064
4,117
Accounts payable
1,995
636.263
-2,269
1,497
1,379
Other working capital
-12,875
-13,879
-14,976
-729.386
-190.009
Other non-cash items
989.503
989.503
41.611
72.188
1,121
Net cash provided by operating activities
-12,868
-13,879
-14,936
-729.386
-190.009
Cash flows from investing activities
Investments in property, plant and equipment
-
-
-39.56
-
-
Net cash used for investing activities
-6.805
0
-39.56
-
-
Cash flows from financing activities
Debt repayment
-349.824
-704.16
-2,213
-
-
Common stock issued
5,491
9,218
14,550
-
-
Other financing activities
-
-
-
-686.701
-260.211
Net cash used provided by (used for) financing activities
7,137
17,397
20,338
503.522
407.479
Net change in cash
-5,738
3,517
5,337
-126.556
213.589
Cash at beginning of period
7,092
5,431
93.711
220.267
6.678
Cash at end of period
1,354
8,948
5,431
93.711
220.267
Free cash flow
Operating cash flow
-12,868
-13,879
-14,936
-729.386
-190.009
Capital expenditure
-
-
-39.56
-
-
Free cash flow
-12,875
-13,879
-14,976
-729.386
-190.009